BioMed Research International / 2011 / Article / Tab 1

Review Article

Histone Deacetylase Inhibitors in the Treatment of Hematological Malignancies and Solid Tumors

Table 1

Table of HDACs inhibitors discussed in this paper, organized by class (refer to text for references).

HDACs inhibitor classHDACs inhibitorsOther common identifiersClinical trial phaseStructure

Small molecular weight carboxylatesValprioc acidDepakene, Depakote, Depakote ER, Depakote SprinkleFDA-approved for epileps, seizures, mania, bipolar disorders, migranes Phase I/II in hematological malignancies and solid tumors475641.table.001a

Hydroxamic AcidsVorinostatSuberoylanilide hydroxamic acid, (SAHA), ZolinzaFDA-approved for CTCL Phase I/II in hematological malignancies and solid tumors475641.table.001b
PanobinostatLBH589Phase I/II in hematological malignancies and solid tumors475641.table.001c
BelinostatPXD101Phase I/II in hematological malignancies and solid tumors475641.table.001d

BenzamidesEntinostatMS-27-275, MS-275, SNDX-275Phase I/II in hematological malignancies and solid tumors475641.table.001e
MGD0103MocetinostatPhase I/II in hematological malignancies and solid tumors475641.table.001f

Cyclic tetrapeptidesRomidepsinDepsipeptide, Istodax, FK228, FR901228FDA-approved for CTCL Phase I/II in hematological malignancies and solid tumors475641.table.001g